A growing number of small biopharma companies are launching drugs independently and trying to build commercial traction. Successful commercial execution is not an easy feat for small companies, which generally have less to spend on commercial infrastructure and fewer resources to tap into.
Key Takeaways
- Several small biopharma companies are launching drugs independently and trying to build commercial traction, not always an easy feat.
- Apellis Pharmaceuticals’ launch of Syfovre for geographic atrophy has gotten off to a strong start despite the emergence of retinal vasculitis
In some cases, these solo launches also represent the company’s first commercial product